Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness

References

• Kaplon H, Reichert JM. Antibodies to watch in 2019. MAbs. 2019;11:219–13. doi:https://doi.org/10.1080/19420862.2018.1556465.
   PubMed Web of Science ®Google Scholar
• Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I–related receptor FcRn. Annu Rev Immunol. 2000;18:739–66. doi:https://doi.org/10.1146/annurev.immunol.18.1.739.
   PubMed Web of Science ®Google Scholar
• Jennewein MF, Alter G. The immunoregulatory roles of antibody glycosylation. Trends Immunol. 2017;38:358–72. doi:https://doi.org/10.1016/j.it.2017.02.004.
   PubMed Web of Science ®Google Scholar
• Chung S, Quarmby V, Gao X, Ying Y, Lin L, Reed C, Fong C, Lau W, Qiu Z, Shen A, et al. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities. MAbs. 2012;4:326–40. doi:https://doi.org/10.4161/mabs.19941.
   PubMed Web of Science ®Google Scholar
• Treffers LW, Van Houdt M, Bruggeman CW, Heineke MH, Zhao XW, Van Der Heijden J, Nagelkerke S, Verkuijlen P, Geissler J, Lissenberg-Thunnissen S, et al. FcγRIIIb restricts antibody-dependent destruction of cancer cells by human neutrophils. Front Immunol. 2018;9:3124. doi:https://doi.org/10.3389/fimmu.2018.03124.
   PubMed Web of Science ®Google Scholar
• Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6:576–88. doi:https://doi.org/10.1002/psp4.12224.
   PubMedGoogle Scholar
• Li T, DiLillo DJ, Bournazos S, Giddens JP, Ravetch JV, Wang LX. Modulating IgG effector function by Fc glycan engineering. Proc Natl Acad Sci U S A. 2017;114:3485–90. doi:https://doi.org/10.1073/pnas.1702173114.
   PubMed Web of Science ®Google Scholar
• Jandus C, Boligan K, Chijioke O, Liu H, Dahlhaus M, Démoulins T, Schneider C, Wehrli M, Hunger RH, Baerlocher GM, et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest. 2014;124:1810–20. doi:https://doi.org/10.1172/JCI65899.
   PubMed Web of Science ®Google Scholar
• Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019;25:656–66. doi:https://doi.org/10.1038/s41591-019-0374-x.
   PubMed Web of Science ®Google Scholar
• Quast I, Keller CW, Maurer MA, Giddens JP, Tackenberg B, Wang LX, Münz C, Nimmerjahn F, Dalakas MC, Lünemann JD. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J Clin Invest. 2015;125:4160–70. doi:https://doi.org/10.1172/JCI82695.
   PubMed Web of Science ®Google Scholar
• Park EI, Manzella SM, Baenziger JU. Rapid clearance of sialylated glycoproteins by the asialoglycoprotein receptor. J Biol Chem. 2003;278:4597–602. doi:https://doi.org/10.1074/jbc.M210612200.
   PubMed Web of Science ®Google Scholar
• Goh JB, Ng SK. Impact of host cell line choice on glycan profile. Crit Rev Biotechnol. 2018;38:851–67. doi:https://doi.org/10.1080/07388551.2017.1416577.
   PubMed Web of Science ®Google Scholar
• Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, Crocker L, Pabonan O, Baginski T, Meng G, et al. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res. 2010;70:4481–89. doi:https://doi.org/10.1158/0008-5472.CAN-09-3704.
   PubMed Web of Science ®Google Scholar
• Schuster M, Umana P, Ferrara C, Brünker P, Gerdes C, Waxenecker G, Wiederkum S, Schwager C, Loibner H, Himmler G, et al. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res. 2005;65:7934–41. doi:https://doi.org/10.1158/0008-5472.CAN-04-4212.
   PubMed Web of Science ®Google Scholar
• Malphettes L, Freyvert Y, Chang J, Liu P, Chan E, Miller J, Zhou Z, Nguyen T, Tsai C, Snowden AW, et al. Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies. Biotechnol Bioeng. 2010;106:774–83. doi:https://doi.org/10.1002/bit.22751.
   PubMed Web of Science ®Google Scholar
• Lin N, Mascarenhas J, Sealover NR, George HJ, Brooks J, Kayser KJ, Gau B, Yasa I, Azadi P, Archer-Hartmann S. Chinese hamster ovary (CHO) host cell engineering to increase sialylation of recombinant therapeutic proteins by modulating sialyltransferase expression. Biotechnol Prog. 2015;31:334–46. doi:https://doi.org/10.1002/btpr.2038.
   PubMed Web of Science ®Google Scholar
• Du J, Meledeo MA, Wang Z, Khanna HS, Paruchuri VDP, Yarema KJ. Metabolic glycoengineering: sialic acid and beyond. Glycobiology. 2009;19:1382–401. doi:https://doi.org/10.1093/glycob/cwp115.
   PubMed Web of Science ®Google Scholar
• Hollevoet K, Declerck PJ. State of play and clinical prospects of antibody gene transfer. J Transl Med. 2017;15:131. doi:https://doi.org/10.1186/s12967-017-1234-4.
   PubMed Web of Science ®Google Scholar
• Jiang M, Shi W, Zhang Q, Wang X,  Guo M, Cui Z, Su C, Yang Q, Li Y, Sham J et al. Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin Cancer Res. 2006;12:6179–85. doi:https://doi.org/10.1158/1078-0432.ccr-06-0746.
   PubMed Web of Science ®Google Scholar
• Rodrigues E, Macauley MS. Hypersialylation in cancer: modulation of inflammation and therapeutic opportunities. Cancers (Basel). 2018;10:207. doi:https://doi.org/10.3390/cancers10060207.
   PubMed Web of Science ®Google Scholar
• Brockhoff G, Heckel B, Schmidt-Brecken E, Plander M, Hofstaedter F, Vollmann A, Diermeier S. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif. 2007;40:488–507. doi:https://doi.org/10.1111/j.1365-2184.2007.00449.x.
   PubMed Web of Science ®Google Scholar
• Yang Y, Liu F, Franc V, Halim LA, Schellekens H, Heck AJR. Hybrid mass spectrometry approaches in glycoprotein analysis and their usage in scoring biosimilarity. Nat Commun. 2016;7:13397. doi:https://doi.org/10.1038/ncomms13397.
   PubMed Web of Science ®Google Scholar
• Franc V, Zhu J, Heck AJR. Comprehensive proteoform characterization of plasma complement component C8αβγ by hybrid mass spectrometry approaches. J Am Soc Mass Spectrom. 2018;29:1099–110. doi:https://doi.org/10.1007/s13361-018-1901-6.
   PubMed Web of Science ®Google Scholar
• Čaval T, Tian W, Yang Z, Clausen H, Heck AJR. Direct quality control of glycoengineered erythropoietin variants. Nat Commun. 2018;9:3342. doi:https://doi.org/10.1038/s41467-018-05536-3.
   PubMed Web of Science ®Google Scholar
• Liu H, Ponniah G, Zhang H, Nowak C, Neil A, Gonzalez-Lopez N, Patel R, Cheng G, Kita AZ, Andrien B. In vitro and in vivo modifications of recombinant and human IgG antibodies. MAbs. 2014;6:1145–54. doi:https://doi.org/10.4161/mabs.29883.
   PubMed Web of Science ®Google Scholar
• Kim S, Song J, Park S, Ham S, Paek K, Kang M, Chae Y, Seo H, Kim H, Flores M. Drifts in ADCC-related quality attributes of Herceptin®: impact on development of a trastuzumab biosimilar. MAbs. 2017;9:704–14. doi:https://doi.org/10.1080/19420862.2017.1305530.
   PubMed Web of Science ®Google Scholar
• Dreier B, Honegger A, Hess C, Nagy-Davidescu G, Mittl P, Grütter MG, Belousova N, Mikheeva G, Krasnykh V, Plückthun A. Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters. Proc Natl Acad Sci U S A. 2013;110:E869–77. doi:https://doi.org/10.1073/pnas.1213653110.
   PubMed Web of Science ®Google Scholar
• Schmid M, Ernst P, Honegger A, Suomalainen M, Zimmermann M, Braun L, Stauffer S, Thom C, Dreier B, Eibauer M, et al. Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control. Nat Commun. 2018;9:450. doi:https://doi.org/10.1038/s41467-017-02707-6.
   PubMed Web of Science ®Google Scholar
• Lyons M, Onion D, Green NK, Aslan K, Rajaratnam R, Bazan-Peregrino M, Phipps S, Hale S, Mautner V, Semour LW, et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther. 2006;14:118–28. doi:https://doi.org/10.1016/j.ymthe.2006.01.003.
   PubMed Web of Science ®Google Scholar
• Petryszak R, Keays M, Tang Y, Fonseca N, Barrera E, Burdett T, Füllgrabe A, Fuentes A, Jupp S, Koskinen S, et al. Expression Atlas update - an integrated database of gene and protein expression in humans, animals and plants. Nucleic Acids Res. 2016;44:D746–D752. doi:https://doi.org/10.1093/nar/gkv1045.
   PubMed Web of Science ®Google Scholar
• Jager L, Hausl MA, Rauschhuber C, Wolf NM, Kay MA, Ehrhardt A. A rapid protocol for construction and production of high-capacity adenoviral vectors. Nat Protoc. 2007;2:1236–47. doi:https://doi.org/10.1038/nprot.2009.4.
   PubMedGoogle Scholar
• Rosewell A, Vetrini F, Ng P. Helper-dependent adenoviral vectors. J Genet Syndr Gene Ther. 2011;Suppl 5:1. doi:https://doi.org/10.4172/2157-7412.s5-001.
   Google Scholar
• Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–07. doi:https://doi.org/10.1038/nature11003.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313:670–73. doi:https://doi.org/10.1126/science.1129594.
   PubMed Web of Science ®Google Scholar
• Pereira NA, Chan KF, Lin PC, Song Z. The “less-is-more” in therapeutic antibodies: afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity. MAbs. 2018;10:693–711. doi:https://doi.org/10.1080/19420862.2018.1466767.
   PubMed Web of Science ®Google Scholar
• Bruggeman CW, Dekkers G, Bentlage AEH, Treffers LW, Nagelkerke SQ, Lissenberg-Thunnissen S, Koeleman CAM, Wuhrer M, van den Berg TK, Rispens T, et al. Enhanced effector functions due to antibody defucosylation depend on the effector cell Fcγ receptor profile. J Immunol. 2017;199:204–11. doi:https://doi.org/10.4049/jimmunol.1700116.
   PubMed Web of Science ®Google Scholar
• Ackerman ME, Crispin M, Yu X, Baruah K, Boesch AWN, Harvey DJ, Dugast AS, Heinzen EL, Eran A, Choi I, et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest. 2013;123:2183–92. doi:https://doi.org/10.1172/JCI65708.
   PubMed Web of Science ®Google Scholar
• Mahan AE, Jennewein MF, Suscovich T, Dionne K, Tedesco J, Chung AW, Streeck H, Pau M, Schuitemaker H, Francis D, et al. Antigen-specific antibody glycosylation is regulated via vaccination. PLoS Pathog. 2016;12:e1005456. doi:https://doi.org/10.1371/journal.ppat.1005456.
   PubMed Web of Science ®Google Scholar
• Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the “high-hanging fruit.”. Nat Rev Drug Discov. 2018;17:197–223. doi:https://doi.org/10.1038/nrd.2017.227.
   PubMed Web of Science ®Google Scholar
• Jung ST, Reddy ST, Kang TH, Borrok MJ, Sandlie I, Tucker PW, Georgiou G. Aglycosylated IgG variants expressed in bacteria that selectively bind FcγRI potentiate tumor cell killing by monocyte-dendritic cells. Proc Natl Acad Sci U S A. 2010;107:604–09. doi:https://doi.org/10.1073/pnas.0908590107.
   PubMed Web of Science ®Google Scholar
• Chen TF, Sazinsky S, Houde D, DiLillo DJ, Bird J, Li KK, Cheng GT, Qiu H, Enge JR, Ravetch JV, et al. Engineering aglycosylated IgG variants with wild-type or improved binding affinity to human Fc gamma RIIa and Fc gamma RIIIAs. J Mol Biol. 2017;429:2528–41. doi:https://doi.org/10.1016/j.jmb.2017.07.001.
   PubMed Web of Science ®Google Scholar
• Ferrara C, Brünker P, Suter T, Moser S, Püntener U, Umaña P. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous β1, 4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II. Biotechnol Bioeng. 2006;93:851–61. doi:https://doi.org/10.1002/bit.20777.
   PubMed Web of Science ®Google Scholar
• Pagan JD, Kitaoka M, Anthony RM. Engineered sialylation of pathogenic antibodies in vivo attenuates autoimmune disease. Cell. 2018;172:564–77. doi:https://doi.org/10.1016/j.cell.2017.11.041.
   PubMed Web of Science ®Google Scholar
• Naso MF, Tam SH, Scallon BJ, Raju TS. Engineering host cell lines to reduce terminal sialylation of secreted antibodies. MAbs. 2010;2:519–27. doi:https://doi.org/10.4161/mabs.2.5.13078.
   PubMed Web of Science ®Google Scholar
• Von Horsten HH, Ogorek C, Blanchard V, Demmler C, Giese C, Winkler K, Kaup M, Berger M, Jordan I, Sandig V, et al. Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-d-lyxo-4-hexulose reductase. Glycobiology. 2010;20:1607–18. doi:https://doi.org/10.1093/glycob/cwq109.
   PubMed Web of Science ®Google Scholar
• Haryadi R, Ho S, Kok YJ, Pu HZ, Zheng L, Pereira NA, Li B, Bi X, Goh L, Yang Y, et al. Optimization of heavy chain and light chain signal peptides for high level expression of therapeutic antibodies in CHO cells. PLoS One. 2015;10:1–16. doi:https://doi.org/10.1371/journal.pone.0116878.
   Web of Science ®Google Scholar
• Chng J, Wang T, Nian R, Lau A, Hoi KM, Ho SCL, Gagnon P, Bi X, Yang Y. Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells. MAbs. 2015;7:403–12. doi:https://doi.org/10.1080/19420862.2015.1008351.
   PubMed Web of Science ®Google Scholar
• Palmer D, Ng P. Improved system for helper-dependent adenoviral vector production. Mol Ther. 2003;8:846–52. doi:https://doi.org/10.1016/j.ymthe.2003.08.014.
   PubMed Web of Science ®Google Scholar
• Rosati S, Yang Y, Barendregt A, Heck AJR. Detailed mass analysis of structural heterogeneity in monoclonal antibodies using native mass spectrometry. Nat Protoc. 2014;9:967–76. doi:https://doi.org/10.1038/nprot.2014.057.
   PubMed Web of Science ®Google Scholar
• Bern M, Caval T, Kil YS, Tang W, Becker C, Carlson E, Kletter D, Sen KI, Galy N, Hagemans D, et al. Parsimonious charge deconvolution for native mass spectrometry. J Proteome Res. 2018;17:1216–26. doi:https://doi.org/10.1021/acs.jproteome.7b00839.
   PubMed Web of Science ®Google Scholar
• Lin Y-H, Zhu J, Meijer S, Franc V, Heck AJR. Glycoproteogenomics: A frequent gene polymorphism affects the glycosylation pattern of the human serum fetuin/α-2-HS-glycoprotein. Mol Cell Proteomics. 2019;18:1479–90. doi:https://doi.org/10.1074/mcp.ra119.001411.
   PubMed Web of Science ®Google Scholar